All News

Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.

Clinical evaluation dictates the need for preventive therapy and advice on exercising and participation in competitive sports, according to the European Society of Cardiology.

Submission is based on phase 2 study results evaluating atogepant in adults who met the primary endpoint of a statistically significant reduction from the baseline compared with a placebo.

Lisocabtagene maraleucel (liso-cel, Breyanzi; Bristol Myers Squibb) approved for the second-line treatment of patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B.

We spoke with Carlie Traylor, PharmD, of the National Community Pharmacy Association to learn about a fellowship program offered by NCPA and CPESN

Venlafaxine Extended-Release (Effexor XR) is indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Suzanne Soliman, PharmD, BCMAS welcomes Sonia T. Oskouei, PharmD, BCMAS, DPLA to discuss biosimilars within the pharmacy industry.

Analysis results expand understanding of the impact of the company’s medicines in early stages with the goal or providing patients with durable and robust outcomes from their first treatment.

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

Breast cancer screening guidelines using mammography vary among guiding bodies, including the American Cancer Society and the American Academy of Family Physicians.

Amy Cadwallader, PhD, director of Regulatory and Public Policy Development at US Pharmacopeia (USP), discusses how medicine quality and the medicines supply chain can affect antimicrobial resistance (AMR).

Abemaciclib (Verzenio; Eli Lilly and Company) is an FDA-approved kinase inhibitor being investigated for new indications in individuals with hormone-sensitive prostate cancer and castration-resistant prostate cancer.

Combination therapy with both nivolumab and relatlimab leads to increased T-cell activation compared with monotherapy with either agent alone.

Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses how HOPA works within and its impact on hematology/oncology pharmacy practice management.

The impact of the pandemic on the mental health of health care workers, including pharmacists and pharmacy staff, has been well documented.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses his research investigating the persistence of taste and smell loss among patients who have been infected and reinfected with COVID-19.

Stephanie Mason believes that pharmacists should expect their involvement in glycemic management to increase in the near future.

Capecitabine (Xeloda) is indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.

Hydrogel Burn Pads provide cooling relief for minor burns and absorbs fluid to prevent infection.

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Vaxneuvance was approved for an expanded indication by the FDA on June 22, 2022, for active immunization in children 6 weeks of age and older.

Simplifying processes reduces errors in compounding, IV pump programming, and physician order entry.

This month's OTC product news features contact lenses for astigmatism, supplements, and children's probiotics.

But investigators find that individuals who had shingles that spread to the central nervous system had nearly twice the risk of developing mental deterioration, though it is rare.

Treatment identifies patients with ROS1 fusion-positive non-small cell lung cancer or those with NTRK fusion-positive solid tumors for whom treatment with Rozlytrek may be appropriate.

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

In clinical trials, dabrafenib and trametinib showed meaningful efficacy in multiple BRAF-positive tumor types, including in patients with rare cancers who have no other treatment options available.